News from synthetic biologics, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Mar 04, 2021, 16:10 ET Synthetic Biologics Reports 2020 Year End Operational Highlights and Financial Results

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to...

Feb 25, 2021, 07:00 ET Synthetic Biologics to Report 2020 Year End Operational Highlights and Financial Results on March 4, 2021

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to...

Dec 22, 2020, 07:00 ET Synthetic Biologics Announces Washington University School of Medicine in St. Louis IRB Approval of the SYN-004 (ribaxamase) Phase 1b/2a Clinical Protocol

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to...

Nov 24, 2020, 07:00 ET Synthetic Biologics Announces Extension of Compliance Plan Period by NYSE American

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to...

Nov 16, 2020, 07:00 ET Synthetic Biologics Engages A.G.P./Alliance Global Partners as Advisor to Assist in Evaluating Strategic Options

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to...

Nov 12, 2020, 07:00 ET Synthetic Biologics Welcomes Senior Biotech Executive John Monahan, PhD, to Board of Directors

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to...

Nov 10, 2020, 16:15 ET Synthetic Biologics Reports 2020 Third Quarter Operational Highlights and Financial Results

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to...

Nov 03, 2020, 16:30 ET Synthetic Biologics to Report 2020 Third Quarter Operational Highlights and Financial Results on November 10, 2020

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to...

Oct 02, 2020, 07:00 ET Synthetic Biologics Provides Update on Investigator-Sponsored Phase 2b Clinical Study of SYN-010 in IBS-C Patients

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to...

Aug 06, 2020, 16:15 ET Synthetic Biologics Reports 2020 Second Quarter Operational Highlights and Financial Results

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to...

Jul 30, 2020, 07:00 ET Synthetic Biologics Announces FDA Clearance of Investigational New Drug Application for SYN-020 Intestinal Alkaline Phosphatase (IAP)

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to...

Jul 29, 2020, 16:30 ET Synthetic Biologics to Report 2020 Second Quarter Operational Highlights and Financial Results on August 6, 2020

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to...

Jun 30, 2020, 07:00 ET Synthetic Biologics Announces Submission of IND Application to U.S. FDA for SYN-020 Intestinal Alkaline Phosphatase

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to...

May 27, 2020, 07:00 ET Synthetic Biologics Enters into Exclusive Option to License Intellectual Property for Use of SYN-020 to Treat and Prevent Age-Related Metabolic and Inflammatory Diseases

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to...

May 05, 2020, 16:15 ET Synthetic Biologics Reports 2020 First Quarter Operational Highlights and Financial Results

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to...

Apr 28, 2020, 16:30 ET Synthetic Biologics to Report 2020 First Quarter Operational Highlights and Financial Results on May 5, 2020

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to...

Feb 20, 2020, 16:15 ET Synthetic Biologics Reports 2019 Year End Operational Highlights and Financial Results

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to...

Feb 13, 2020, 07:00 ET Synthetic Biologics to Report 2019 Year End Operational Highlights and Financial Results on February 20, 2020

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to...

Feb 07, 2020, 16:30 ET Synthetic Biologics Announces Acceptance of Compliance Plan by NYSE American

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to...

Feb 04, 2020, 07:00 ET Synthetic Biologics to Present at the 2020 BIO CEO & Investor Conference

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to...

Jan 07, 2020, 07:00 ET Synthetic Biologics Receives FDA Guidance at Type C Meeting for SYN-004 (ribaxamase) Phase 1b/2a Clinical Trial in Allogeneic HCT Recipients

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to...

Nov 27, 2019, 16:30 ET Synthetic Biologics Reports on NYSE American Noncompliance Notice and Compliance Plan

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to...

Nov 04, 2019, 16:10 ET Synthetic Biologics Reports Third Quarter 2019 Operational Highlights and Financial Results

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to...

Oct 28, 2019, 16:30 ET Synthetic Biologics to Report 2019 Third Quarter Operational Highlights and Financial Results on November 4, 2019

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to...

Sep 26, 2019, 07:00 ET Synthetic Biologics Strengthens U.S. Patent Coverage of SYN-010, Intended for the Novel Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)

Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and...